Biomarker Analysis in Post-COVID Patients

The requested reference [215bb7bb16a77aa7ca23ac510a883967765057de] no longer exists in our database. It has been replaced by the current reference: [f571f57e1967080c8a1870d8405d5f940113c580]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.
Epistemonikos ID: 19ff2a8c2750d1be1beae83f84d88b878179b78d
First added on: May 02, 2023